CureDuchenne Ventures Invests in hC Bioscience and its Novel tRNA-Based Therapeutic Approach for Duchenne Muscular Dystrophy
There is no excerpt because this is a protected post.
CureDuchenne was the original funder of cTAP. We congratulate the consortium and other authors on their recent publication looking at large data sources and investigating effects of different genotypes on […]
Entrada Therapeutics announced the selection of a second clinical candidate, ENTR-601-45, for the potential treatment of people living with Duchenne who are exon 45 skipping amenable. Read more in the […]
Pratteln, Switzerland, and Rockville, MD, USA, October 27, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that they have completed the rolling submission of a new drug […]
We are pleased to announce that six sites are open for enrollment for the Canyon trial for individuals living with Becker Muscular Dystrophy! Canyon is a Phase 2 trial of […]
See full PRESS RELEASE: https://www.globenewswire.com/news-release/2022/10/13/2534198/0/en/PepGen-Presents-Data-from-its-Duchenne-Muscular-Dystrophy-Program-at-World-Muscle-Society-Congress.html
Dyne Therapeutics, who received early funding from CureDuchenne, presented promising preclinical data from their Duchenne Exon 51 and 53 programs at the World Muscle Society Congress. This was Dyne’s first […]